A development that may evolve into a revolution in medicine: MRNA as the basis for novel, nucleotide-based vaccines and drugs

Therapeutic Advances in Vaccines

Volumn 2, Issue 1, 2014, Pages 10-31

  Kallen, Karl Josef ^a   Theß, Andreas ^a  

^a CureVac GmbH   (Germany)

Author keywords

MRNA based vaccines; Replicons; RNActive vaccines; Therapeutic mRNA

Indexed keywords

EID: 84921025620     PISSN: 20510136     EISSN: None     Source Type: Journal    
DOI: 10.1177/2051013613508729     Document Type: Review

References (161)

1. Anderson, B., Muramatsu, H., Nallagatla, S., Bevilacqua, P., Sansing, L., Weissman, D. et al. (2010) Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 38: 5884–5892
2. Anraku, I., Harvey, T., Linedale, R., Gardner, J., Harrich, D., Suhrbier, A. et al. (2002) Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 76: 3791–3799
3. Aoshi, T., Koyama, S., Kobiyama, K., Akira, S. and Ishii, K.J. (2011) Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol 1: 226–232
4. Bagarazzi, M., Yan, J., Morrow, M., Shen, X., Parker, R., Lee, J. et al. (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4: 155ra138
5. Banerjee, A. (1980) 5′-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev 44: 175–205
6. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S. et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974–977
7. Bauer, R., Scheiblhofer, S., Kern, K., Gruber, C., Stepanoska, T., Thalhamer, T. et al. (2006) Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol 118: 269–276
8. Bedikian, A., Richards, J., Kharkevitch, D., Atkins, M., Whitman, E. and Gonzalez, R. (2010) A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20: 218–226
9. Bendtzen, K. (2012) Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy 4: 1167–1179
10. Benteyn, D., Van Nuffel, A., Wilgenhof, S., Corthals, J., Heirman, C., Neyns, B. et al. (2013) Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013: 976383
11. Berglund, P., Fleeton, M., Smerdou, C. and Liljeström, P. (1999) Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17: 497–507
12. Berglund, P., Smerdou, C., Fleeton, M., Tubulekas, I. and Liljeström, P. (1998) Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16: 562–565
13. Bernstein, D., Cardin, R., Bravo, F., Earwood, J., Clark, J., Li, Y. et al. (2012) Topical SMIP-7.7, a tolllike receptor 7 agonist, protects against genital herpes simplex virus-2 disease in the guinea pig model of genital herpes. Antivir Chem Chemother 12 December (Epub ahead of print).
14. Biankin, A., Waddell, N., Kassahn, K., Gingras, M., Muthuswamy, L., Johns, A. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399–405
15. Boczkowski, D., Nair, S., Snyder, D. and Gilboa, E. (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465–472
16. Bonehill, A., Heirman, C., Tuyaerts, S., Michiels, A., Zhang, Y., van der Bruggen, P. et al. (2003) Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res 63: 5587–5594
17. Bonehill, A., Tuyaerts, S., Van Nuffel, A., Heirman, C., Bos, T., Fostier, K. et al. (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16: 1170–1180
18. Breckpot, K., Dullaers, M., Bonehill, A., van Meirvenne, S., Heirman, C., de Greef, C. et al. (2003) Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 5: 654–667
19. Breckpot, K., Heirman, C., Neyns, B. and Thielemans, K. (2004) Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 6: 1175–1188
20. Castle, J., Kreiter, S., Diekmann, J., Lower, M., van de, Roemer, N., de Graaf, J. et al. (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72: 1081–1091
21. Christensen, C. (1997) The innovator’s dilemma: when new technologies cause great firms to fail (management of innovation and change). Watertown, MA: Harvard Business Review Press.
22. Conry, R., LoBuglio, A., Wright, M., Sumerel, L., Pike, M., Johanning, F. et al. (1995) Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55: 1397–1400
23. Davis, B., Chang, G., Cropp, B., Roehrig, J., Martin, D., Mitchell, C. et al. (2001) West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75: 4040–4047
24. Day, K., Sweeny, L., Kulbersh, B., Zinn, K. and Rosenthal, E. (2013) Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol 29 May (Epub ahead of print).
25. Desmet, C. and Ishii, K. (2012) Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 12: 479–491
26. Diamond, M., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G., Archambault, J. et al. (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208: 1989–2003
27. Diebold, S., Schulz, O., Alexopoulou, L., Leitner, W., Flavell, R. and Reis e Sousa, C. (2009) Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther 16: 359–366
28. Diken, M., Kreiter, S., Selmi, A., Britten, C., Huber, C., Tureci, O. et al. (2011) Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 18: 702–708
29. Diken, M., Kreiter, S., Selmi, A., Tureci, O. and Sahin, U. (2013) Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies. Methods Mol Biol 969: 235–246
30. Dubensky, T., Jr, Driver, D., Polo, J., Belli, B., Latham, E., Ibanez, C. et al. (1996) Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 70: 508–519
31. Dunn, G., Old, L. and Schreiber, R. (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329–360
32. Ferraro, B., Talbott, K., Balakrishnan, A., Cisper, N., Morrow, M., Hutnick, N. et al. (2013) Inducing humoral and cellular responses to multiple sporozoite and liver stage malaria antigens using pDNA. Infect Immun 81: 3709–3720
33. Finnegan, G. (2012) Europe risks ‘vaccine fatigue’. Vaccines today 8 October.
34. Fleeton, M., Chen, M., Berglund, P., Rhodes, G., Parker, S., Murphy, M. et al. (2001) Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183: 1395–1398
35. Fleeton, M., Liljeström, P., Sheahan, B. and Atkins, G. (2000) Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 81: 749–758
36. Fotin-Mleczek, M., Duchardt, K., Lorenz, C., Pfeiffer, R., Ojkic-Zrna, S., Probst, J. et al. (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34: 1–15
37. Fotin-Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. et al. (2012) Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med 14: 428–439
38. Garver, K., LaPatra, S. and Kurath, G. (2005) Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis Aquat Organ 64: 13–22
39. Geall, A., Mandl, C. and Ulmer, J. (2013) RNA: The new revolution in nucleic acid vaccines. Semin Immunol 25: 152–159
40. Geall, A., Verma, A., Otten, G., Shaw, C., Hekele, A., Banerjee, K. et al. (2012) Nonviral delivery of selfamplifying RNA vaccines. Proc Natl Acad Sci U S A 109: 14604–14609
41. Gilboa, E. (2007) DC-based cancer vaccines. J Clin Invest 117: 1195–1203
42. Gilboa, E. (2012) mRNA leapfrogs DNA to show promise for therapeutic gene transfer. Mol Ther 20: 694–695
43. Gilboa, E. and Vieweg, J. (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199: 251–263
44. Gould, H. and Sutton, B. (2008) IgE in allergy and asthma today. Nat Rev Immunol 8: 205–217
45. Grosenbaugh, D., Leard, A., Bergman, P., Klein, M., Meleo, K., Susaneck, S. et al. (2011) Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72: 1631–1638
46. Gulley, J. and Drake, C. (2011) Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 17: 3884–3891
47. Han, S., Asoyan, A., Rabenstein, H., Nakano, N. and Obst, R. (2010) Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci U S A 107: 20453–20458
48. Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C., Creyghton, M. et al. (2009) Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462: 595–601
49. Hariharan, M., Driver, D., Townsend, K., Brumm, D., Polo, J., Belli, B. et al. (1998) DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 72: 950–958
50. Hartmann, E., Graefe, H., Hopert, A., Pries, R., Rothenfusser, S., Poeck, H. et al. (2006) Analysis of plasmacytoid and myeloid dendritic cells in nasal epithelium. Clin Vaccine Immunol 13: 1278–1286
51. Hartmann, E., Wollenberg, B., Rothenfusser, S., Wagner, M., Wellisch, D., Mack, B. et al. (2003) Identification and functional analysis of tumorinfiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63: 6478–6487
52. Hekele, A., Bertholet, S., Archer, J., Gibson, D., Palladino, G., Brito, L. et al. (2013) Rapidly produced SAMH vaccine against H7N9 influenza is immunogenic in mice. Emerging Microbes and Infections 2: e52
53. Henrickson, S., Mempel, T., Mazo, I., Liu, B., Artyomov, M., Zheng, H. et al. (2008) T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol 9: 282–291
54. Hoerr, I., Obst, R., Rammensee, H. and Jung, G. (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30: 1–7
55. Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C. et al. (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108: 4009–4017
56. Iavarone, C., Ramsauer, K., Kubarenko, A., Debasitis, J., Leykin, I., Weber, A. et al. (2011) A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J Immunol 186: 4213–4222
57. Johanning, F., Conry, R., LoBuglio, A., Wright, M., Sumerel, L., Pike, M. et al. (1995) A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res 23: 1495–1501
58. Johansson, D., Ljungberg, K., Kakoulidou, M. and Liljeström, P. (2012) Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 7: e29732
59. Julkunen, I., Sareneva, T., Pirhonen, J., Ronni, T., Melen, K. and Matikainen, S. (2001) Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev 12: 171–180
60. Kallen, K., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A. et al. (2013) A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines. Hum Vaccin Immunother 9: 2263–2276
61. Kariko, K., Buckstein, M., Ni, H. and Weissman, D. (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165–175
62. Kariko, K., Muramatsu, H., Keller, J. and Weissman, D. (2012) Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridinecontaining mRNA encoding erythropoietin. Mol Ther 20: 948–953
63. Kariko, K., Muramatsu, H., Welsh, F., Ludwig, J., Kato, H., Akira, S. et al. (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16: 1833–1840
64. Kariko, K. and Weissman, D. (2007) Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 10: 523–532
65. Ketterer, T., von der Mülbe, F., Reidel, L. and Mutzke, T. (2008) Method for purifying RNA on a preparative scale by means of HPLC. Patent WO2008077592
66. Kharfan-Dabaja, M., Boeckh, M., Wilck, M., Langston, A., Chu, A., Wloch, M. et al. (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12: 290–299
67. Killela, P., Reitman, Z., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L., Jr et al. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110: 6021–6026
68. Kirman, J., Turon, T., Su, H., Li, A., Kraus, C., Polo, J. et al. (2003) Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 71: 575–579
69. Kormann, M., Hasenpusch, G., Aneja, M., Nica, G., Flemmer, A., Herber-Jonat, S. et al. (2011) Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154–157
70. Koski, G., Kariko, K., Xu, S., Weissman, D., Cohen, P. and Czerniecki, B. (2004) Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 172: 3989–3993
71. Kreiter, S., Castle, J., Tureci, O. and Sahin, U. (2012) Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 1: 768–769
72. Kreiter, S., Diken, M., Selmi, A., Tureci, O. and Sahin, U. (2011) Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23: 399–406
73. Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C., Huber, C. et al. (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70: 9031–9040
74. Kreiter, S., Selmi, A., Diken, M., Sebastian, M., Osterloh, P., Schild, H. et al. (2008) Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 180: 309–318
75. Kübler, H., Maurer, T., Stenzl, A., Feyerabend, S., Steiner, U., Schostak, M. et al. (2011) Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. J Clin Oncol 29(Suppl.): abstract 4535
76. Kuhn, A., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J. et al. (2010) Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 17: 961–971
77. Kurath, G., Garver, K., Corbeil, S., Elliott, D., Anderson, E. and LaPatra, S. (2006) Protective immunity and lack of histopathological damage two years after DNA vaccination against infectious hematopoietic necrosis virus in trout. Vaccine 24: 345–354
78. Lee, J., Sayed, N., Hunter, A., Au, K., Wong, W., Mocarski, E. et al. (2012) Activation of innate immunity is required for efficient nuclear reprogramming. Cell 151: 547–558
79. Leitner, W., Hwang, L., deVeer, M., Zhou, A., Silverman, R., Williams, B. et al. (2003) Alphavirusbased DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9: 33–39
80. Leitner, W., Ying, H., Driver, D., Dubensky, T. and Restifo, N. (2000) Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60: 51–55
81. Lindsay, C., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncol 9: 825–829
82. Ljung, R. (2013) Hemophilia and prophylaxis. Pediatr Blood Cancer 60(Suppl. 1): S23–S26
83. Lorenz, C., Fotin-Mleczek, M., Roth, G., Becker, C., Dam, T., Verdurmen, W. et al. (2011) Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 8: 627–636
84. Madan, R., Bilusic, M., Heery, C., Schlom, J. and Gulley, J. (2012) Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 39: 296–304
85. Mandal, P. and Rossi, D. (2013) Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc 8: 568–582
86. Marichal, T., Ohata, K., Bedoret, D., Mesnil, C., Sabatel, C., Kobiyama, K. et al. (2011) DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 17: 996–1002
87. Martinon, F., Krishnan, S., Lenzen, G., Magne, R., Gomard, E., Guillet, J. et al. (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23: 1719–1722
88. Mbow, M., De Gregorio, E., Valiante, N. and Rappuoli, R. (2010) New adjuvants for human vaccines. Curr Opin Immunol 22: 411–416
89. Moots, R. and Naisbett-Groet, B. (2012) The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 51: 2252–2261
90. Morse, M., Hobeika, A., Osada, T., Berglund, P., Hubby, B., Negri, S. et al. (2010) An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 120: 3234–3241
91. Naik, S., Metcalf, D., van Nieuwenhuijze, A., Wicks, I., Wu, L., O’Keeffe, M. et al. (2006) Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 7: 663–671
92. Neyns, B., Wilgenhof, S., Van Nuffel, A., Benteyn, D. and Corthals, J., Heirman, C. et al. (2012) Phase IB study on combined intradermal (ID) and intravenous (IV) administration of autologous mRNA electroporated dendritic cells (DC) as a singleagent cellular immunotherapy or combined with ipilimumab. J Clin Oncol 30(Suppl.): abstract 2507
93. O’Neill, D., Adams, S. and Bhardwaj, N. (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104: 2235–2246
94. Okada, T., Miller, M., Parker, I., Krummel, M., Neighbors, M., Hartley, S. et al. (2005) Antigenengaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 3: e150
95. Panjarian, S., Iacob, R., Chen, S., Engen, J. and Smithgall, T. (2013) Structure and dynamic regulation of Abl kinases. J Biol Chem 288: 5443–5450
96. Pascolo, S. (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4: 1285–1294
97. Pascolo, S. (2006) Vaccination with messenger RNA. Methods Mol Med 127: 23–40
98. Petsch, B., Schnee, M., Vogel, A., Lange, E., Hoffmann, B., Voss, D. et al. (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30: 1210–1216
99. Pichlmair, A., Schulz, O., Tan, C., Naslund, T., Liljeström, P., Weber, F. et al. (2006) RIG-Imediated antiviral responses to single-stranded RNA bearing 5’-phosphates. Science 314: 997–1001
100. Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T. et al. (2013) Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 21: 251–259
101. Quintas-Cardama, A. and Jabbour, E. (2013) Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib. Leuk Res 37: 487–495
102. Rehwinkel, J., Tan, C., Goubau, D., Schulz, O., Pichlmair, A., Bier, K. et al. (2010) RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 140: 397–408
103. Rittig, S., Haentschel, M., Weimer, K., Heine, A., Muller, M., Brugger, W. et al. (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19: 990–999
104. Robak, T. (2012) Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 12: 503–515
105. Roesler, E., Weiss, R., Weinberger, E., Fruehwirth, A., Stoecklinger, A., Mostbock, S. et al. (2009) Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 124: 1070–1077 e1071-1011
106. Russo, C., Cornella-Taracido, I., Galli-Stampino, L., Jain, R., Harrington, E., Isome, Y. et al. (2011) Small molecule toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells. Blood 117: 5683–5691
107. Sardesai, N. and Weiner, D. (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23: 421–429
108. Schadendorf, D., Ugurel, S., Schuler-Thurner, B., Nestle, F., Enk, A., Brocker, E. et al. (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17: 563–570
109. Scheel, B., Teufel, R., Probst, J., Carralot, J., Geginat, J., Radsak, M. et al. (2005) Toll-like receptordependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35: 1557–1566
110. Scheiblhofer, S., Gabler, M., Leitner, W., Bauer, R., Zoegg, T., Ferreira, F. et al. (2006a) Inhibition of type I allergic responses with nanogram doses of repliconbased DNA vaccines. Allergy 61: 828–835
111. Scheiblhofer, S., Thalhamer, J. and Weiss, R. (2013) Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. Expert Opin Drug Deliv 10: 761–773
112. Scheiblhofer, S., Weiss, R., Gabler, M., Leitner, W. and Thalhamer, J. (2006b) Replicase-based DNA vaccines for allergy treatment. Methods Mol Med 127: 221–235
113. Schlake, T., Thess, A., Fotin-Mleczek, M. and Kallen, K. (2012) Developing mRNA-vaccine technologies. RNA Biol 9: 1319–1330
114. Schulz, O., Diebold, S., Chen, M., Naslund, T., Nolte, M., Alexopoulou, L. et al. (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887–892
115. Sebastian, M., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, et al. (2011) Messenger RNA vaccination in NSCLC: findings from a phase I/IIa clinical trial. J Clin Oncol 29(Suppl.): abstract 2584
116. Sebastian, M., von Boehmer, L., Zippelius, A., Mayer, F. and Reck, M., Atanackovic, D. et al. (2012) Messenger RNA vaccination and B-cell responses in NSCLC patients.. J Clin Oncol 30(Suppl.): abstract 2573
117. Sellam, J., Rouanet, S., Hendel-Chavez, H., Miceli- Richard, C., Combe, B., Sibilia, J. et al. (2013) CCL19, a B-cell chemokine, is related to the decrease of blood memory B-cells and predicts the clinical response to rituximab in rheumatoid arthritis. Arthritis Rheum 65: 2253–2261
118. Shin, H. and Wherry, E. (2007) CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 19: 408–415
119. Slovin, S., Kehoe, M., Durso, R., Fernandez, C., Olson, W., Gao, J. et al. (2013) A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostatespecific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 31: 943–949
120. Specenier, P. and Vermorken, J. (2013) Cetuximab: its unique place in head and neck cancer treatment. Biologics 7: 77–90
121. Spranger, S., Frankenberger, B. and Schendel, D. (2012) NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med 10: 30
122. Spranger, S., Javorovic, M., Burdek, M., Wilde, S., Mosetter, B., Tippmer, S. et al. (2010) Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 185: 738–747
123. Sullenger, B. and Gilboa, E. (2002) Emerging clinical applications of RNA. Nature 418: 252–258
124. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872
125. Takahashi, K. and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676
126. Takatsu, K. and Nakajima, H. (2008) IL-5 and eosinophilia. Curr Opin Immunol 20: 288–294
127. Tang, D., DeVit, M. and Johnston, S. (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152–154
128. Thalhamer, T., Dobias, H., Stepanoska, T., Proll, M., Stutz, H., Dissertori, O. et al. (2010) Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. J Allergy Clin Immunol 125: 926–934 e910
129. Ulmer, J., Donnelly, J., Parker, S., Rhodes, G., Felgner, P., Dwarki, V. et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745–1749
130. Ulmer, J., Mason, P., Geall, A. and Mandl, C. (2012) RNA-based vaccines. Vaccine 30: 4414–4418
131. Vaine, M., Wang, S., Crooks, E., Jiang, P., Montefiori, D., Binley, J. et al. (2008) Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82: 7369–7378
132. Van den Bosch, G., Van Gulck, E., Ponsaerts, P., Nijs, G., Lenjou, M., Apers, L. et al. (2006) Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNAelectroporated CD40-activated autologous B-cells. J Immunother 29: 512–523
133. Van Gulck, E., Vlieghe, E., Vekemans, M., Van Tendeloo, V., Van De Velde, A., Smits, E. et al. (2012) mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1- infected patients. AIDS 26: F1–F12
134. Vanham, G. and Van Gulck, E. (2012) Can immunotherapy be useful as a ’functional cure‘ for infection with human immunodeficiency virus-1? Retrovirology 9: 72
135. Van Lint, S., Goyvaerts, C., Maenhout, S., Goethals, L., Disy, A., Benteyn, D. et al. (2012) Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72: 1661–1671
136. Van Lint, S., Heirman, C., Thielemans, K. and Breckpot, K. (2013) mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9: 265–274
137. Van Nuffel, A., Benteyn, D., Wilgenhof, S., Corthals, J., Heirman, C., Neyns, B. et al. (2012a) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61: 1033–1043
138. Van Nuffel, A., Benteyn, D., Wilgenhof, S., Pierret, L., Corthals, J., Heirman, C. et al. (2012b) Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 20: 1063–1074
139. Van Nuffel, A., Wilgenhof, S., Thielemans, K. and Bonehill, A. (2012c) Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy. Oncoimmunology 1: 1392–1394
140. Vogelstein, B., Papadopoulos, N., Velculescu, V., Zhou, S., Diaz, L., Jr and Kinzler, K. (2013) Cancer genome landscapes. Science 339: 1546–1558
141. Wallner, M., Hauser, M., Himly, M., Zaborsky, N., Mutschlechner, S., Harrer, A. et al. (2011) Reshaping the Bet v 1 fold modulates T(H) polarization. J Allergy Clin Immunol 127: 1571–1578 e1579
142. Walsh, K., Teijaro, J., Zuniga, E., Welch, M., Fremgen, D., Blackburn, S. et al. (2012) Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection. Cell Host Microbe 11: 643–653
143. Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C. et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18: 1254–1261
144. Wang, S., Kishko, M., Wan, S., Wang, Y., Brewster, F., Gray, G. et al. (2012) Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates. Hum Vaccin Immunother 8: 1638–1647
145. Warren, L., Manos, P., Ahfeldt, T., Loh, Y., Li, H., Lau, F. et al. (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618–630
146. Weide, B., Carralot, J., Reese, A., Scheel, B., Eigentler, T., Hoerr, I. et al. (2008) Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31: 180–188
147. Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. et al. (2009) Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32: 498–507
148. Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E. and Thalhamer, J. (2012) mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 11: 55–67
149. Weiss, R., Scheiblhofer, S. and Thalhamer, J. (2006) DNA vaccines for allergy treatment. Methods Mol Med 127: 253–267
150. Wherry, E., Blattman, J., Murali-Krishna, K., van der Most, R. and Ahmed, R. (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911–4927
151. Wickens, M. (1990) How the messenger got its tail: addition of poly(A) in the nucleus. Trends Biochem Sci 15: 277–281
152. Wilgenhof, S., Pierret, L., Corthals, J., Van Nuffel, A., Heirman, C., Roelandt, T. et al. (2011a) Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases. Melanoma Res 21: 152–159
153. Wilgenhof, S., Van Nuffel, A., Corthals, J., Heirman, C., Tuyaerts, S., Benteyn, D. et al. (2011b) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34: 448–456
154. Wilgenhof, S., Van Nuffel, A., Benteyn, D., Corthals, J., Aerts, C., Heirman, C. et al. (2013) Phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24: 2686–2693
155. Wolff, J., Malone, R., Williams, P., Chong, W., Acsadi, G., Jani, A. et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465–1468
156. Wollenberg, A., Wagner, M., Gunther, S., Towarowski, A., Tuma, E., Moderer, M. et al. (2002) Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119: 1096–1102
157. Xiong, C., Levis, R., Shen, P., Schlesinger, S., Rice, C. and Huang, H. (1989) Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243: 1188–1191
158. Yakubov, E., Rechavi, G., Rozenblatt, S. and Givol, D. (2010) Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 394: 189–193
159. Yu, J., Vodyanik, M., Smuga-Otto, K., Antosiewicz- Bourget, J., Frane, J., Tian, S. et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920
160. Zangi, L., Lui, K., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. et al. (2013) Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 8 September (Epub ahead of print).
161. Zhou, X., Berglund, P., Rhodes, G., Parker, S., Jondal, M. and Liljeström, P. (1994) Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12: 1510–1514.